Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) EBT Margin: 2020-2025

Historic EBT Margin for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to 0.83%.

  • Xeris Biopharma Holdings' EBT Margin rose 3596.00% to 0.83% in Q3 2025 from the same period last year, while for Sep 2025 it was -5.88%, marking a year-over-year increase of 2915.00%. This contributed to the annual value of -28.12% for FY2024, which is 1062.00% up from last year.
  • Xeris Biopharma Holdings' EBT Margin amounted to 0.83% in Q3 2025, which was up 130.98% from -2.70% recorded in Q2 2025.
  • Xeris Biopharma Holdings' 5-year EBT Margin high stood at 0.83% for Q3 2025, and its period low was -308.95% during Q2 2021.
  • For the 3-year period, Xeris Biopharma Holdings' EBT Margin averaged around -27.07%, with its median value being -29.66% (2024).
  • In the last 5 years, Xeris Biopharma Holdings' EBT Margin slumped by 6,502bps in 2021 and then spiked by 20,414bps in 2022.
  • Xeris Biopharma Holdings' EBT Margin (Quarterly) stood at -237.02% in 2021, then surged by 19,698bps to -40.03% in 2022, then soared by 934bps to -30.70% in 2023, then spiked by 2,219bps to -8.51% in 2024, then soared by 3,596bps to 0.83% in 2025.
  • Its EBT Margin stands at 0.83% for Q3 2025, versus -2.70% for Q2 2025 and -15.34% for Q1 2025.